1	Im	plementing an antibiogram profile to aid rational antimicrobial therapy and
2	im	proving infection prevention in an urban hospital in The Gambia; strategies and
3	les	sons for low income and middle-income countries.
4		
5	Au	ithors:
6	Sa	ffiatou Darboe ¹ , Ruel Mirasol ² , Babapelumi Adejuyigbe ³ , Abdul Khalie Muhammad ¹ ,
7	Be	hzad Nadjm ^{1,4} , Annabelle de St Maurice ⁵ , Tiffany L. Dogan ⁶ , Buntung Ceesay ¹ , Solomon
8	Ur	nukoro ¹ , Uduak Okomo ¹ , Davis Nwakanma ¹ , Anna Roca ¹ , Ousman Secka ¹ , Karen Forrest ¹
9	an	d Omai B. Garner ² (on behalf of MRCG/UCLA collaborative working group)
10		
11	Af	filiations
12	1.	Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
13		Medicine
14	2.	Department of Pathology and Laboratory Medicine, University of California Los Angeles,
15		Los Angeles, California, USA
16	3.	David Geffen School of Medicine, University of California, Los Angeles, Los Angeles,
17		California, UCLA
18	4.	University College London Hospital NHS Foundation Trust, London, UK
19	5.	Department of Pediatrics, Division of Infectious Diseases, David Geffen School of
20		Medicine, UCLA
21	6.	Department of Clinical Epidemiology and Infection Prevention, University of California,
22		Los Angeles, California, UCLA Health

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Saffiatou Darboe

26 Medical Research Council Unit The Gambia at London School of Hygiene and	Tropical
---	----------

- 27 Medicine, P.O Box 273 Banjul, The Gambia.
- 28 email: Saffiatou.Darboe@lshtm.ac.uk

29

- **30** Alternative Corresponding Author
- 31 Dr Omai Garner.
- 32 <u>ogarner@mednet.ucla.edu</u>
- 33

34 **Running title:**

- 35 Developing and implementing an antibiogram profile in The Gambia
- 36

37 Key words:

- 38 Cumulative antibiogram, antimicrobial resistance (AMR), Infection prevention and control
- 39 (IPC), low- and middle-income countries (LMICs), *Escherichia coli* (E. coli), *Staphylococcus*
- 40 aureus (S. aureus), Klebsiella pnuemonaie (K. pneumoniae) bacteraemia, urinary tract
- 41 infection (UTI)

43 Abstract:

44 Background: Diagnostic microbiological capabilities remain a challenge in low- and middle-45 income countries resulting in major gaps. The global antimicrobial resistance burden has 46 necessitated use of appropriate prescribing to curb the menace. This study highlights the 47 process used to develop an antibiogram to monitor resistance at a secondary-level health 48 facility to aid empirical clinical decision making.

49 Methods: This retrospective cross-sectional descriptive study used 3 years of cumulative data 50 at the Medical Research Council Unit The Gambia from January 2016 to December 2018. 51 Phenotypic data was manually imputed into WHONET and the cumulative antibiogram 52 constructed using standardised methodologies according to CLSI M39-A4 guidelines. 53 Pathogens were identified by standard microbiological methods and antimicrobial 54 susceptibility testing was performed using Kirby-Bauer disc diffusion method according to 55 CLSI M100 guidelines.

Results: A total of 14776 non-duplicate samples (blood cultures n=4382, urines n=4914, other 56 miscellaneous swabs and aspirates n=2821 and n=390 respectively, sputa n=334, stools 57 n=1463, CSF 353 and other samples n= 119) were processed of which 1163 (7.9%) were 58 positive for clinically significant pathogens. Among the 1163 pathogens, E. coli (n= 315) S. 59 aureus (n=232), and K. pneumoniae (n=96) were the leading cause of disease Overall, the 60 susceptibility for E. coli and K. pneumoniae from all samples were: trimethoprim-61 sulfamethoxazole (17% and 28%), tetracycline (26% and 33%), gentamicin (72% and 46%), 62 chloramphenicol (76 and 60%), and ciprofloxacin (69% and 59%), amoxicillin/clavulanic 63 (77% and 54%) respectively. Extended spectrum beta-lactamase resistance was present in 23% 64 (71/315) vs 35% (34/96) respectively. S. aureus susceptibility for methicillin was 99%. 65

- 66 **Conclusion**: This antibiogram has confirmed susceptibility to commonly used antimicrobials
- 67 was higher for *E. coli* than *K. pneumoniae* with high ESBL resistance warranting surveillance.
- 68 An alternative aminoglycoside with better sensitivity such as amikacin might be relevant
- although this was not tested and that cloxacillin remains a drug of choice for the Staphylococci.

70 Introduction:

Antimicrobial resistance (AMR) is recognised as a global health threat requiring appropriate 71 containment strategies with sub-Saharan Africa (sSA) disproportionately affected [1,2]. 72 Multiple factors transcending disciplines contribute to the development of AMR, with 73 inappropriate use of antibiotics regarded as a major contributing factor according to the report 74 by the WHO Global Action Plan on antimicrobial resistance [3]. Surveillance is key in 75 76 understanding the epidemiology of AMR to inform appropriate public health intervention and control. Containment strategies including monitoring antibiotic usage, monitoring resistance 77 78 patterns, using appropriate guidelines for treatment, and establishing effective infection prevention and control (IPC) are essential. Thus, multistakeholder collaboration to combat 79 AMR is required. Active surveillance is paramount in monitoring resistance trends and can be 80 81 an effective, data driven strategy for evidence-based decision making [4].

82 The cumulative antibiogram periodically summarises a healthcare facility's antimicrobial 83 susceptibility profiles for public health surveillance to identify changes in trends and aid 84 clinicians in making informed empiric therapeutic choices relative to local context [5]. Furthermore, antibiograms are useful in detecting potential infectious disease outbreaks. The 85 86 use of such aggregate data on local or regional resistance trends is fundamental to discern differences and changes in patterns for appropriate selection of antimicrobials for rational use 87 and epidemiological surveillance [1,6]. Thus, diagnostics remain key in combating AMR. 88 However, in low and middle income countries (LMIC), major gaps exist ranging from limited 89 90 expertise, infrastructure, investment and lack of institutional microbiologic diagnostic 91 capabilities [7,8]. In addition, many countries in sub-Saharan Africa have not prioritized AMR preparedness and implementation of the global action plan to tackle AMR [9,10]. Furthermore, 92 93 IPC measures to reduce hospital associated infections and antimicrobial resistance surveillance 94 are fundamental for an integrated health system strengthening approach. The understanding of 95 the clinical implications of resistance patterns and interpretation of an antibiogram is 96 paramount for clinical decision making. Thus, the diagnostic microbiology lab must ensure that 97 the antibiogram is generated in collaboration with physicians, pharmacists, and other infectious 98 diseases professionals for improved antimicrobial stewardship [11]. Additionally, antibiogram 99 data must be generated from quality-assured clinical diagnostic microbiology laboratories 100 using guidelines such as the Clinical Laboratory Standards Institute (CLSI) M39-A4 consensus 101 document [12] to ensure reliability for better patient outcomes.

102 Considering this, the Medical Research Council Unit The Gambia at LSTHM 103 (MRCGatLSHTM) and University of California, Los Angeles (UCLA) formed a working 104 group to support microbiological diagnostic capabilities and implementation of an antibiogram 105 to aid empiric therapy and IPC to improve antimicrobial stewardship. This project has provided 106 evidence for the feasibility of harnessing collaborative technical support for implementing 107 AMR stewardship in a sub-Saharan African country.

108 Methods and Materials:

109 Study design and setting:

This study was cross-sectional descriptive analysis of the cumulative antibiogram over a period of three years (January 2016 to December 2018), using data from the Clinical Microbiology Laboratory at the Clinical Services Department (CSD) of the MRCG at LSHTM in The Gambia. A multidisciplinary team of microbiologists, physicians, epidemiologists, and IPC specialists across the collaborating institutions met over several months to review available data.

116 The Gambia is the smallest mainland African country in West Africa with a population of 2.1

million with high malnutrition and decreasing malaria incidence [13–15].

The CSD has a 42-bed capacity ward and an Outpatient Department seeing approximately 50,000 adult and paediatric patients annually. The CSD provides primary and secondary-level care to sick individuals from the surrounding population with complicated cases referred to the main tertiary government hospitals. No surgical departments, obstetrics, or Intensive Care Units are present with limited neonatal admissions. It is the only facility in the Gambia with consistent routine microbiological testing capabilities for patients with suspected invasive infections.

125 Microbiological procedures

Samples were processed in the diagnostic microbiology laboratory, which is both Good Clinical Laboratory Practice (GCLP; 2010) certified and ISO15189 (2015) accredited. Standard microbiological processing of samples and identification procedures were regularly performed according to standard microbiological protocols. Blood culture samples were routinely collected in BD Bactec aerobic and anaerobic adult and paediatric bottles respectively. Positive bottles were cultured on blood, chocolate and MacConkey agar plates and drops put on microscopic slides for Gram staining. Growth on plates were further

characterised and identified using biochemical reagents. Pathogens considered contaminants 133 such as coagulase negative staph, isolated >1 time and confirmed causative agents for infective 134 endocarditis (IE) were considered. The Duke criteria for diagnosing infective endocarditis were 135 used to determine pathogenicity of the viridans group Strep isolates. Blood and cerebrospinal 136 fluid (CSF) samples are routinely collected for bacterial culture from patients presenting with 137 suspected sepsis and meningitis, respectively. Microbiological data is considered community 138 139 acquired as samples are collected upon presentation and long stays are rare. In addition, first isolate for patient was considered for analysis. Data is reported and stored in a local electronic 140 141 medical record system (EMRS). Selective reporting of antimicrobials is yet to be introduced and specimens were anonymised for confidentiality prior to analysis. 142

Urine samples were considered clinically significant when growth $>10^5$ of a single organism. 143 Urines were primarily cultured on cysteine lactose electrolyte deficient (CLED) and incubated 144 145 overnight at 37°C, followed by appropriate pathogen identification if growth was $> 10^5$ CFUs. Other samples were cultured on appropriate agar plates such as blood, chocolate, MacConkey, 146 147 sabouraud dextrose and Thayer-martin agar plates as indicated. Isolates were identified using appropriate biochemical tests; Enterobacterales were identified using BioMerieux API20E, 148 149 other non-enteric Gram-negative were identified using API20NE. Staphylococcus aureus (S. 150 aureus) were identified using Staphaurex Plus and mannitol salt agar testing. Streptococcus pneumoniae (S. pneumoniae) was confirmed using optochin disc, with confirmatory testing 151 using bile solubility. Haemophilus influenzae (H. influenzae) was identified using X and V 152 153 factors and serological testing. In addition, beta-haemolytic group Streptococci were identified using Streptex/Wellcogen serological test. Antimicrobial susceptibility patterns were 154 determined by Kirby-Bauer disk diffusion on Mueller-Hinton agar and zone sizes interpreted 155 according to the relevant Clinical Laboratory Standard Institute (CLSI) guidelines on 156 antimicrobial agents [16]. Appropriate American Type Culture Collection (ATCC) controls E. 157

coli 25922, *P. aeruginosa* 29835, *S. aureus* 25923 and *S. pneumoniae* 49616 were consistently
used as quality control organisms for the antibiotic susceptibility testing and reagent
performance verification.

161 Analysis

Data were extracted from the Electronic Medical Record System (EMRS), uploaded into 162 WHONET, cross-checked for unusual susceptibility patterns, verified as per CLSI M39 [12] 163 and cleaned. All pathogens isolated during the period considered as individual infection 164 episodes were included. Isolates from successive cultures from different body sites were 165 reviewed and the first isolate included as per the CLSI guideline. Data was stratified by 166 specimen type for blood and Urine and analysed. Heat maps were generated to visually 167 highlight resistance patterns and bar charts to show differences in organism frequencies among 168 samples. Tables were generated to show cumulative antibiograms for use and implement 169 antimicrobial prescription guideline. [12]. 170

171 Ethical review and approval

The study is part of an ongoing microbiological improvement project to implement localprescribing guideline and antimicrobial stewardship at the MRCG at LSHTM.

174 **Results:**

175 Samples and pathogen distribution:

- 176 Over the 3-year period, a total of 14,776 different specimens were received and processed
- 177 (Figure 1, flowchart), of which 1163 clinically significant organisms were isolated. Urine and
- blood cultures accounted for one-third (n=4914) and (n=4382) of the samples respectively.

Results of 182 blood cultures, (4.2%) were considered clinically significant (Figure 2a). The 179 leading cause of bacteraemia were E. coli (n=40) and S. aureus (n=39) responsible for 22.0% 180 181 and 21.4% respectively (Figure 2b). This was followed by non-typhoidal Salmonella (NTS) (n=16), S. pneumoniae (n=15), Enterococcus species (n=15), and Pseudomonas species other 182 than P. aeruginosa (n=10) (Table 1). From urine samples, 9.0% were confirmed clinically 183 184 relevant (n=442) (Figure 2a). Among the causes of UTI, 55.4% were E. coli (n=245) and 12.7% were K. pneumoniae (n=56) (Figure 2b) followed by other coliform bacteria (n=31), Candida 185 species (n=26), Enterococcus faecalis n=16 and Streptococcus agalactiae n=14 (Table 2). 186

Out of 2821 swabs, a total of 381 (13.5%) were considered clinically significant. The swabs 187 were further stratified into eye, ear, nose & throat (EENT) n=1628, skin/wound n=1131 and 188 urogenital n=62 (Figure 1). When stratified according to swab type, 1.2% pathogens were 189 recovered from EENT (n=19), 3.2% of pathogens were recovered from skin/wound (n=355) 190 and 11.3% from urogenital swabs (n=7). The leading pathogens from EENT were *H. influenzae* 191 non-type b (n=5), K. pneumoniae (n=4) and S. pneumoniae (n=4) (Supplementary figure 1). 192 For skin/wound swab, the leading pathogens were S. aureus (n=148), Pseudomonas aeruginosa 193 194 (n=39) and S. pyogenes (n=38). From urogenital swabs, S. agalactiae (4/7) and N. gonorrhoea (3/7) were recovered. Among the 390 aspirates, 12.6% (n=49) were considered clinically 195 significant. They were stratified into abscess (n=25) and aspirates from invasive sterile sites 196 197 (n=365). Pathogenic organisms were recovered from 96% abscesses (24/25) and 6.8% of

198 invasive aspirates (25/365). The organisms from abscesses were 83.3% S. aureus (n=20), one each of Morganella morganii, NTS, Streptococcus group F and K. pneumoniae. Among 25 199 pathogens from invasive sterile aspirates, *Streptococci* species (n=7) and S. *aureus* (n=7) were 200 most prevalent, followed by other coliform bacteria (n=4), two S. pneumoniae and two 201 Pseudomonas species (Supplementary figure 2). Among 334 sputa samples, 26.0% were 202 positive for a pathogen (n=87). The leading pathogens were H. influenzae non-type b n=20 203 204 (23%) and K. pneumoniae n=17 (19.5%) (Figure 2b). Over the time period studied, only (1.7%) of 353 CSF grew pathogens (n=6) of which four were S. pneumoniae, one E. coli and one 205 206 *Pseudomonas* species. Among the stool samples, 13 pathogens were isolated of which (n=10) were NTS. 207

Overall, E. coli (27.1% of the pathogens) and S. aureus (19.9%) and were found to be the 208 leading cause of disease in our setting (Figure 2b) followed by Klebsiella pneumoniae 8.3% 209 (n=96), *Pseudomonas aeruginosa* (n=57), other coliform bacteria (n=52), *Streptococcus* 210 211 pyogenes (n=45), Enterococcus species (n=43), Pseudomonas species other than aeruginosa (n=43), Proteus species (n=41), Streptococcus pneumoniae (n=31) and Klebsiella species other 212 than pneumoniae (n=30), non-typhoidal Salmonella (n=28) and Streptococcus agalactiae 213 (n=27) (Figure 2b). E coli was prevalent in urine, blood and swabs whilst S. aureus was 214 prevalent in swabs, blood and aspirates. In addition, K. pneumoniae was prevalent in urine, 215 sputum and swabs. 216

217 Susceptibility profiles of pathogens

Susceptibility patterns for the common pathogens found in blood and/or urinary pathogens for
various antimicrobials was varied (Table 1 for blood culture and Table 2 for urinary pathogens).
The major causative agents for UTI were highly susceptible to nitrofurantoin (94%). Overall,
the *Enterobacterales* (except NTS) susceptibility to ampicillin was 11% for *E. coli* and 44%

for Proteus species. Susceptibilities to 3rd generation cephalosporins for E. coli and K. 222 pneumoniae were 86% and 54%, for cephamycin 97.8% and 97.9% and for the beta-lactamase 223 inhibitor clavulanic acid 77.2% and 65% respectively. ESBL resistance was present 23% 224 (71/315) vs 35% (34/96) for E. coli and K. pneumoniae respectively. Susceptibilities to 225 226 chloramphenicol, ciprofloxacin and gentamicin for E. coli were 75.7%, 72.7% and 75.9% respectively. For K. pneumoniae 60%, 63.5%, 53.2% and for S. aureus 97.3%, 98.9%, 95.2% 227 respectively (Figure 3). Remarkably, susceptibility for methicillin for S. aureus was very high 228 99.4% but low for penicillin 20.2%. S. pneumoniae and H. influenzae were susceptible to 229 230 penicillin 77.4% and ampicillin 100% respectively but low for trimethoprim-sulfamethoxazole (0%). Penicillin susceptibility for Enterococcus was 81.4%. S. agalactiae and S. pyogenes 231 susceptibilities were 100% susceptible for penicillin but for tetracycline 33.3% and 29.6.% 232 233 respectively. These susceptibility profiles are shown in the heatmap depicting increasing resistance with from purple to red (Figure 3) 234

235 **Discussion:**

This study provides an antibiogram profile from the diagnostic microbiology laboratory for 236 clinical samples over a three-year period in The Gambia to aid in empirical clinical decision 237 making. This is part of a collaborative network between the MRCG, and UCLA set out to 238 improve microbiological laboratory capacity and improve IPC. Diagnostic microbiological 239 capabilities with standardised methodologies and expertise for detection and management of 240 241 AMR are often scarce in many LMICs [6,17]. The global action plan on antimicrobial resistance highlights inappropriate prescribing as one of the main drivers of AMR [3], thus, the 242 243 implementation of this antibiogram is paramount in understanding resistance dynamics to aid rational local prescribing. The antibiogram is particularly useful when the infecting organism 244 is known prior to susceptibility patterns. With the global spread of antimicrobial 245 resistance[2,18], it is a useful tool to monitor local changes to provide evidence-base data for 246 local prescribing guidelines. However, it is important that ways of disseminating the 247 information to all prescribers are facilitated for easy access in prescribing areas. It is also 248 important that users are educated in its effective use and effect on patient outcome [19] and 249 thus this study facilitated that in a local hospital. 250

251 In this study, E. coli and S. aureus were found to be the most prevalent cause of all disease and in particular bacteraemia. It is important to note that S. aureus remains a prevalent cause of 252 bacteraemia [15,20] as seen in other parts of globe [21,22]. However, E. coli is for the first 253 time being reported in the top two bacteraemia pathogens, taking over from S. pneumoniae as 254 reported previously [15,20]. In addition, it remains the prevalent cause of UTIs. The reduced 255 256 importance of S. pneumoniae as a cause of bacteraemia in The Gambia is attributed to the increasing impact of pneumococcal conjugate vaccines over the years after a higher prevalence 257 of children have been vaccinated [23,24]. The vaccine effectiveness studies done in The 258 259 Gambia have shown both substantial reduction in incidence of pneumococcal bacteraemia

among young children [24] and in pneumonia hospitalisation [25]. Invasive NTS remains a major cause of bacteraemia albeit with low resistance found in this setting. Notwithstanding, the geographical differences noted for NTS serovars and resistance patterns in previous studies ([26,27] warrant advances in surveillance and monitoring to provide information on prescribing.

The coagulase negative *Staphylococci* and viridan group *Streptococci* were mainly considered contaminant unless in patients with underlying conditions such as infective endocarditis, malignancy and neutropenia after meeting criteria for clinical relevance [28]. It is particularly important to state that quality improvement to reduce contaminant rates and improved collection techniques to increase yield in blood cultures is also ongoing.

270 The urine samples harboured the most common bacterial isolates with E. coli, K. pneumoniae and other coliforms as the leading cause of community acquired UTI. Patients were not 271 stratified by age, sex, symptoms or with co-morbidities as this was beyond the scope of this 272 study. A more robust study considering these factors is warranted considering it's a significant 273 cause of morbidity and burden in The Gambia [29,30]. It is important to note that the use of 274 275 indwelling catheters is uncommon in this setting. However, the overall causes of UTIs in The 276 Gambia are of Gram-negative origin as in other studies [31-33]. Enterococcus faecalis and Streptococcus agalactiae was also found to cause disease. 277

The susceptibilities for *E. coli* were similar for both disease syndromes except for ciprofloxacin which was comparatively lower for urinary tract strains (69% vs 85%) than for blood strains. This warrants further investigation into the genomic epidemiology of this important invasive pathogen. Although susceptibility profiles for *E. coli* and other *Enterobacterales* remain high except for *K. pneumoniae*, lower susceptibility is reported in this study than previously for ciprofloxacin, gentamicin, chloramphenicol, and 3^{rd} generation cephalosporins [15]. However,

the lower ciprofloxacin susceptibility profile seen for *E. coli* in UTI compared to bacteraemia 284 deserves further investigation and characterisation. Multidrug resistance was evident especially 285 for ampicillin, tetracycline and trimethoprim-sulfamethoxazole. Both Gram-negative and 286 Gram-positive pathogens had low susceptibilities profiles for trimethoprim-sulfamethoxazole 287 and tetracycline making these ineffective in our setting. It is worth highlighting that 288 carbapenem resistance is yet to be established routinely. Importantly, in the era of the decline 289 290 of pneumococcal meningitis and bacteraemia ([15,24,25], we continue to find increasing resistance to penicillin in this study highlighting the need for surveillance. 291

292 The WHO recommended empiric drug of choice for sepsis remain for ampicillin and gentamicin. This data therefore provides evidence for the modification of this combination to 293 include cloxacillin and amakicin. S. aureus remains susceptible to cefoxitin, the proxy for 294 methicillin and show that cloxacillin remains effective in our setting as previously described 295 [15,34–36]. Penicillin, tetracycline, and trimethoprim-sulfamethoxazole susceptibility 296 297 however was low for most pathogens including S. aureus. These drugs are widely available to the public and misused due to lack of regulation. The emerging penicillin resistance warrant 298 further surveillance and highlights the need for improved microbiologic diagnostic capabilities 299 300 and local antibiogram for appropriate antimicrobials. However, implementation of appropriate IPC interventions and adherence to guidelines with supporting diagnostic evidence remains a 301 major challenge in sub-Saharan Africa [37]. 302

In the advent of AMR, data on local context could be used to inform therapeutic guidelines and improve prescribing and impact on stewardship. To overcome the challenges of AMR, it is important to employ a combination of strategies including improving sanitation to reduce infections episodes, use of guidelines for standardized diagnostic methodologies, and improved expertise and knowledge in understanding the threat posed by this silent pandemic. In

additions, reducing infections through improving hygiene and strengthening IPC in hospitals 308 is a key intervention strategy in curbing the spread of resistance. In resource limited settings 309 where there has been an increase in empiric treatment with WHO 'reserve' antibiotics [3], the 310 knowledge and use of a local antibiogram and investing in infection prevention control are 311 paramount for the management of AMR. In addition, the key involvement of the microbiology 312 leads with insight into the clinical relevance of the results generated has added value into this 313 314 interpretation. It is important that laboratory staff are aware of the public health and clinical significance of their findings [38]. The inclusion and involvement of physicians in the process 315 316 was useful in understanding of the interpretation of the antibiogram and facilitated implementation in routine prescribing as recommended [39]. 317

This study highlights the feasibility of implementing AMR containment strategies to improve 318 prescribing guideline in a LMIC and has provided evidence that multistakeholder collaborative 319 effort could improve antimicrobial stewardships across borders. The implementation of the 320 321 cumulative antibiogram using standardised methodology for the first time is a great opportunity to further disseminate the knowledge and skills across the entire country. This has important 322 implications for antimicrobial stewardship policy. There are several limitations in this study 323 that may hinder its general applicability. First, although the first isolates for patient was 324 included in the analysis, it did not reveal if sample was collected at point of admission or during 325 admission. Hence, we could not reliably identify a potential hospital associated infection. 326 Second, the data was not stratified by age and risk factors. Thirdly, time of sample collection 327 was not documented. Notwithstanding, this antibiogram data has shown high susceptibility 328 329 profiles for pathogens of public health significance. We have also demonstrated that engagement and multistakeholder collaboration can be harnessed to solve global challenges 330 331 such as AMR. We have shown that common antimicrobials are still effective in this setting but 332 importantly, evidence for an improvement in combination therapy is warranted locally.

333 Funding

- This work is supported by the MRCGatLSHTM and the UCLA. The source of funding has no
- role in the design and writing of the manuscript.

336 **Conflict of interest:**

337 The authors declare no conflict of interest

338 Acknowledgement:

- 339 We thank staff of Clinical Services Department and Clinical Laboratories for their support,
- 340 comments, and suggestions.

341 **Contributors:**

342 SD, DN, KF and OG designed the study. SD and OG wrote the draft manuscript. SD did the 343 laboratory analysis and cleaned the data; SD, BA, AKM, RM and OG analysed the data 344 prepared the tables and figures; BN and KF provided clinical care to the patients and facilitated 345 implementation of the antibiogram into clinical practice; All authors critically reviewed and 346 contributed to the manuscript.

- 348 * Other members of the MRCG/UCLA collaborative working group:
- 349 Usman Nurudeen Ikumapayi
- 350 Rasheed Salaudeen
- 351 Mamina Bojang
- 352 Patrick Okot
- 353 Edwin Kamau

References

354	1.	WHO. Organization World Health. Global Strategy for Containment of Antimicrobial
355		Resistance. World Heal Organ. 2001;105.
356	2.	Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global
357		burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet.
358		2022;6736(21).
359	3.	WHO. Global action plan on antimicrobial resistance. World Heal Organ. 2017;1–28.
360	4.	WHO. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report
361		2021. 2021.
362	5.	Handler JF, Stelling J et al. Analysis and presentation of cumulative antibiograms: A
363		new consensus guideline from the Clinical and Laboratory Standards Institute. Clin
364		Infect Dis. 2007;44(6):867–73.
365	6.	Avdic E, Carroll KC et al. The role of the microbiology laboratory in antimicrobial
366		stewardship programs. Infect Dis Clin North Am. 2014;28(2):215–35.
367	7.	Archibald LK, Reller LB. Clinical microbiology in developing countries. In: Emerging
368		Infectious Diseases. 2001.
369	8.	Petti CA, Polage CR, Quinn TC, et al. Laboratory medicine in Africa: A barrier to
370		effective health care. Vol. 42, Clinical Infectious Diseases. 2006.
371	9.	Elton L, Thomason MJ, Tembo J et al. Antimicrobial resistance preparedness in sub-
372		Saharan African countries. Antimicrob Resist Infect Control. 2020;9(1).
373	10.	Iwu CD, Patrick SM. An insight into the implementation of the global action plan on

374	antimicrobial r	resistance	in the	WHO	African	region:	A	roadmap	for	action.	Int	J
375	Antimicrob Ag	gents. 2021	;58(4)									

376	11.	Truong WR, Hidayat L, Bolaris MA, Nguyen L, Yamaki J. The antibiogram: key
377		considerations for its development and utilization. JAC-Antimicrobial Resist. 2021;3(2).
378	12.	CLSI. M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility
379		Test Data ; Approved Guideline — Fourth Edition. Clin Lab Stand Inst. 2014;(January).
380	13.	Review TGC. The Gambia Country Review: Key Data. Gambia Ctry Rev. 2009;
381	14.	Ceesay SJ, Casals-Pascual C et al. Continued decline of malaria in The Gambia with
382		implications for elimination. PLoS One. 2010;5(8):e12242.
383	15.	Darboe S, Okomo U et al. Community-acquired Invasive Bacterial Disease in Urban
384		Gambia , 2005 – 2015 : A Hospital-based Surveillance. Clin Infect Dis. 2019;69(Suppl
385		2):105–13.
386	16.	CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth
387		Informational Supplement. CLSI Document M100-S25. Clinical and Laboratory
388		Standards Institute. 2015.
389	17.	Tadesse BT, Ashley EA, et al. Antimicrobial resistance in Africa: A systematic review.
390		BMC Infect Dis. 2017;17(616).
391	18.	van Boeckel T, Pires J et al. Global Trends in Antimicrobial Resistance in Animals in
392		Low- and Middle-income Countries. Science (80-). 2019;365(6459).

19. Lacy MK, Klutman NE, Horvat RT, Zapantis A. Antibiograms: New NCCLS
guidelines, development, and clinical application. Hosp Pharm. 2004;39(6):542–53.

- 395 20. Hill PC, Onyeama CO et al. Bacteraemia in patients admitted to an urban hospital in
 396 West Africa. BMC Infect Dis. 2007;7:2–10.
- 21. Laupland KB, Lyytikäinen O et al. The changing epidemiology of Staphylococcus
 aureus bloodstream infection: A multinational population-based surveillance study. Clin
 Microbiol Infect. 2013;19(5)(5):465–71.
- Laupland KB, Gregson DB et al. Burden of community-onset bloodstream infection: A
 population-based assessment. Epidemiol Infect. 2007;
- Cutts FT, Zaman SMA et al. Efficacy of nine-valent pneumococcal conjugate vaccine
 against pneumonia and invasive pneumococcal disease in The Gambia: Randomised,
 double-blind, placebo-controlled trial. Lancet. 2005;
- 405 24. Mackenzie GA, Hill PC et al. Effect of the introduction of pneumococcal conjugate
 406 vaccination on invasive pneumococcal disease in The Gambia: a population-based
 407 surveillance study. Lancet Infect Dis. 2016;16(6):703–11.
- 408 25. Mackenzie GA, Hill PC et al. Impact of the introduction of pneumococcal conjugate
 409 vaccination on pneumonia in The Gambia: population-based surveillance and case410 control studies. Lancet Infect Dis. 2017;17(9)(9):965–73.
- 411 26. Kanteh A, Sesay AK et al. Invasive atypical non-typhoidal Salmonella serovars in The
 412 Gambia. Microb Genomics. 2021;7(11).
- 413 27. Darboe S, Bradbury R et al. Genomic diversity and antimicrobial resistance among non414 typhoidal Salmonella associated with human disease in The Gambia. Microb Genomics.
 415 2022;8(3):1–13.
- 416 28. Su TY, Lee MH et al. The clinical impact of patients with bloodstream infection with

417	different groups of Viridans group streptococci by using matrix-assisted laser desorption
418	ionization-time of flight mass spectrometry (MALDI-TOF MS). Med (United States).
419	2018;97(50).

- 420 29. Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol.
 421 2020;38(11).
- 422 30. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary
 423 tract infections. Vol. 11, Therapeutic Advances in Urology. 2019.
- 424 31. Uwaezuoke SN, Ndu IK et al. The prevalence and risk of urinary tract infection in
 425 malnourished children: A systematic review and meta-Analysis. BMC Pediatr.
 426 2019;19(1).
- 427 32. Erdem I, Kara Ali R et al. Community-acquired lower urinary tract infections: Etiology,
 428 antimicrobial resistance, and treatment results in female patients. J Glob Infect Dis.
 429 2018;10(3).
- 430 33. Donkor ES, Horlortu PZ et al. Community acquired urinary tract infections among
 431 adults in Accra, Ghana. Infect Drug Resist. 2019;12.

432 34. Darboe S, Dobreniecki S, Jarju S et al. Prevalence of Panton-Valentine Leukocidin
433 (PVL) and Antimicrobial Resistance in Community-Acquired Clinical Staphylococcus
434 aureus in an Urban Gambian Hospital: A 11-year period retrospective pilot study. Front
435 Cell Infect Microbiol. 2019;9(170).

436 35. Armitage EPEP, Senghore E, Darboe S, Barry M, Camara J, Bah S, et al. High burden
437 and seasonal variation of paediatric scabies and pyoderma prevalence in the Gambia: A
438 cross-sectional study. PLoS Negl Trop Dis. 2019;13(10):1–16.

439	36.	Odutola A, Bottomley C, Zaman SA, Lindsay J, Shah M, Hossain I, et al.
440		Staphylococcus aureus bacteremia in children of rural areas of The Gambia, 2008–2015.
441		Emerg Infect Dis. 2019;25(4).
442	37.	Bediako-Bowan AAA, Owusu E et al. Antibiotic use in surgical units of selected
443		hospitals in Ghana: A multi-centre point prevalence survey. BMC Public Health.
444		2019;19(1).
445	38.	El-Azizi M, Mushtaq A et al. Evaluating antibiograms to monitor drug resistance. Emerg
446		Infect Dis. 2005;11(8):1301–2.
447	39.	Ambretti S, Gagliotti C et al. Reporting epidemiology of antibiotic resistance. Microbiol
448		Medica. 2015;30(2).
449	Figur	e legends and tables
450	Figure	e 1: Flow chart showing distribution of the different samples
450 451	Figure	e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant
450 451 452	Figure Figure	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered
450 451 452 453	Figure Figure	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type
450 451 452 453 454	Figure Figure Figure	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type e 3: Heatmap showing the intensity of resistance patterns for the different pathogens.
450 451 452 453 454 455	Figure Figure Figure	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type e 3: Heatmap showing the intensity of resistance patterns for the different pathogens. Purple depicting susceptibility and increasing resistance shown from yellow to red
450 451 452 453 454 455	Figure Figure Figure Suppl	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type e 3: Heatmap showing the intensity of resistance patterns for the different pathogens. Purple depicting susceptibility and increasing resistance shown from yellow to red ementary figure 1: Bar chart showing the percentage of pathogens recovered from the
450 451 452 453 454 455 456 457	Figure Figure Figure Suppl	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type e 3: Heatmap showing the intensity of resistance patterns for the different pathogens. Purple depicting susceptibility and increasing resistance shown from yellow to red ementary figure 1: Bar chart showing the percentage of pathogens recovered from the various swabs
450 451 452 453 454 455 456 457	Figure Figure Figure Suppl	 e 1: Flow chart showing distribution of the different samples e 2a: Graph showing total number of samples received against clinically significant pathogens recovered e 2b: Bar chart showing proportion of pathogenic organisms by sample type e 3: Heatmap showing the intensity of resistance patterns for the different pathogens. Purple depicting susceptibility and increasing resistance shown from yellow to red ementary figure 1: Bar chart showing the percentage of pathogens recovered from the various swabs ementary figure 2: Bar chart showing the absolute numbers for the pathogens recovered

Table 1: Susceptibility profile for the common blood culture pathogens

Table 2: Susceptibility profile for the urine pathogens







464



Supplementary figure 1 Bar chart showing the pathogen (%) recovered from the sv



466

Supplementary figure 2

Bar chart showing the pathogens numbers recovered from aspira



467

Organism	NUMBER							%	Susce	ptibili	ity						
Gram-negatives		PEN	AMP	SXT	CN	CHL	TET	CIP	CXM	ERY	PB	ОХ	FOX	СТХ	CAZ	VA	AMC
E. coli	40	Na	13	15	83	85	38	85	38	Na	Na	Na	97	90	88	Na	80
NTS	16*	Na	100	88	94	100	88	100	100	Na	Na	Na	100	100	100	Na	100
Pseudomonas species	10*	Na	Na	22	90	22	63	89	50	Na	Na	Na	NA	Na	100	Na	Na
Gram-positives																	
S. aureus	39	13	Na	69	97	97	74	100	Na	87	Na	100	100	Na	Na	100	Na
S. pneumoniae	15*	80	Na	7	Na	93	67	Na	Na	93	Na	80	Na	Na	Na	100	Na
Enterococcus species	15*	92	92	Na	Na	83	58	83	Na	58	Na	Na	Na	Na	Na	100	Na

471 *Less than the recommended number of 30 isolates

Table 2. Susceptibility profile for urine pathogens

Organism	Number	ber % Susceptibility																
Gram-negatives		PEN	AMP	OB	OX	SXT	CN	ТЕТ	F300	CIP	ERY	CXM	CAZ	СТХ	FOX	AMC	PB	VA
E coli	245	Na	11	Na	Na	16	72	26	97	69	Na	78	88	84	98	77	Na	Na
K. pneumoniae	56	Na	0	Na	Na	16	46	33	80	59	Na	29	41	40	96	54	Na	Na
Coliform species	31	Na	7	Na	Na	23	87	38	100	83	Na	74	80	87	87	61	Na	Na
Klebsiella species	14*	Na	0	Na	Na	7	36	57	79	57	Na	36	50	50	100	29	Na	Na
Gram-positives																		
Candida species	26*	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na
Enterococcus species	16*	94	88	Na	Na	Na	Na	13	94	75	81	Na	Na	Na	Na	Na	Na	94
S. agalactiae	14*	100	100	Na	Na	86	Na	7	100	100	100	Na	Na	Na	Na	Na	Na	100
S. aureus	12*	58	Na	100	100	58	100	92	100	100	100	NA	Na	Na	100	Na	Na	100
	1 1	1 6.00	 .															

475 *Less than the recommended number of 30 isolates